Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: JDN who wrote (747)	8/3/1999 3:39:00 PM
From: out_of_the_loop	Respond to of 5582

OK, JDN; it just does not seem like the most efficient way to go about it, especially if you wanted to ask the pharmacist. He/she may not even be the one doing the ordering in most cases. Most definitely that is the case in any chain store bigger than a mom & pop. I have no problem trying to call buyers. It's a question of having information vs. having quality information. The other cold medicines on the shelf are not new brand remedies, are they? The store probably has a seasonal variation in the standing order with those manufacturers and/or distributors. Even though colds have some seasonality, there is year-round demand for the products. Well, maybe next year there won't be such a demand for all the others - lol.

To: JDN who wrote (747)	8/3/1999 11:39:00 PM
From: Bo Didley	Read Replies (2) \| Respond to of 5582

Excellent Post from Dan - OVERVIEW OF GUMM's FUTURE 1. Zicam will be available in nearly every major drug store, grocery store, and mass retailer for the upcoming cold season. The company estimates that between 35,000 and 50,000 stores will have Zicam on the shelf within the next 3 to 4 months. 2. Zicam will be distributed internationally very soon. 3. The Zicam study has been submitted for review to the NEJM. Based on my DD, I think the odds significantly favor that it will be accepted and published. 4. Clinical studies are underway to determine if Zicam is an effective preventative against the common cold and if it alleviates the symptoms of allergies. 5. GumTech's entry into the nicotine gum market is one of their top priorities. Smith-Kline Beecham dominates this market but their patent ran out a couple of months ago. GumTech is in the process of submitting an ANDA to the FDA so they can make a generic form of nicotine gum for the domestic market. They are also in discussions to make nicotine gum for foreign distribution, and this does not require an FDA approved ANDA. The nicotine gum market is estimated at about $800 million and grew at a rate of roughly 65% in the first quarter of 1999. 6. GumTech's sales more than doubled from Q1 98 to Q1 99 and they are very close to their break even point. Much of the company's operating expenses are fixed costs and their margins should improve considerably when their quarterly sales get above $2.75 million. Their sales were $2.45 million in Q1 99. 7. Estimates are that GumTech's sales could reach $80 million to $100 million in the year 2000, primarily due to Zicam and nicotine gum. Depending on the product mix, I estimate that sales in that range would translate to profits between $1.70 and $2.60 per share. All of these factors are driving the price, IMO. If they meet the sales estimates, I think the stock will trade much higher. Obviously everyone doesn't believe that they will meet these projections. Some are brave enough to short the stock based on their belief. I'm long the stock because I think that the company will be successful with Zicam and nicotine gum. BTW, I have used Zicam and found it to be effective, especially when used soon after I feel a cold starting. Best of luck, Dan